EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach

Melina Sophie Kurte, Ann-Cathrine Siefen, Florian Jakobs, Bastian von Tresckow iD, Hans Christian Reinhardt iD, Florian Kron iD

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14095 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Melina Sophie Kurte und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Duisburg-Essen, Essen, Germany. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Incyte Biosciences Germany GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The treatment of relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) changed remarkably since the European Medicines Agency‐approved chimeric antigen receptor T‐cell (CAR‐T) therapies (axicabtagene ciloleucel [axi‐cel], lisocabtagene maraleucel [liso‐cel], tisagenlecleucel [tisa‐cel]) for the third‐line onwards (3+L), and targeted therapies (polatuzumab vedotin–bendamustine–rituximab [pola‐BR], tafasitamab–lenalidomide [Tafa‐L]) for the second‐line (2L) onwards. As associated rising treatment costs represent an economic burden, the cost‐effectiveness of transplant‐ineligible R/R DLBCL interventions was assessed from a German healthcare payer's perspective, using the efficiency frontier (EF) approach.

Methods

A systematic literature review was performed to determine the clinical benefit concerning median overall survival (OS) of bendamustine–rituximab (BR), rituximab–gemcitabine–oxaliplatin (R‐GemOx), axi‐cel, liso‐cel, tisa‐cel, pola‐BR, and Tafa‐L. First‐year treatment costs (drug and medical services costs) were calculated. Results were merged on two‐dimensional graphs illustrating 2L and 3+L EFs.

Results

Second‐line EF is formed by BR (median OS 11.49 months, €23 958) and Tafa‐L (45.7, €104 541), 3+L EF is formed by R‐GemOx (12.0, €29 080), Tafa‐L (15.5, €104 541), and axi‐cel (18.69, €308 516). These interventions build the respective cost‐effectiveness thresholds for novel interventions.

Conclusions

Using the EF approach, the currently most cost‐effective interventions (based on cost‐effectiveness ratios) in the indication of R/R DLBCL were identified to guide international reimbursement decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseHumansCost-Effectiveness AnalysisBendamustine HydrochlorideRituximabImmunotherapy, AdoptiveAntigens, CD19

Stichwörter der Autor:innen

CAR-T-cell therapyDLBCLcost-effectivenessdiffuse large B-cell lymphomaefficiency frontier

Substanzen

Bendamustine HydrochlorideRituximabAntigens, CD19

Autor:innen und Institutionen

  • Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.
  • VITIS Healthcare Group, Cologne, Germany.
  • Department of Haematology and Stem Cell Transplantation, Faculty of Medicine and University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Center for Integrated Oncology (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

ORCID-Profile: Bastian von Tresckow, Hans Christian Reinhardt, Florian Kron

Förderung

  • Incyte Biosciences Germany GmbH

Zitieren

APA

Kurte, M. S., Siefen, A. C., Jakobs, F., von Tresckow, B., Reinhardt, H. C., & Kron, F. (2023). Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach. European Journal of Haematology. https://doi.org/10.1111/ejh.14095

Vancouver

Kurte MS, Siefen AC, Jakobs F, von Tresckow B, Reinhardt HC, Kron F. Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach. European Journal of Haematology. 2023. doi:10.1111/ejh.14095

BibTeX
@article{Kurte2023,
  author = {Kurte, Melina Sophie and Siefen, Ann-Cathrine and Jakobs, Florian and von Tresckow, Bastian and Reinhardt, Hans Christian and Kron, Florian},
  title = {Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14095}
}
Kostenlos starten →